PEPTIDE GUARDIANResearch literacy for peptides

Guides

Hormonal and reproductive: what the research shows

Compounds that act on reproductive hormones or sexual function. This guide covers 2 of them. For each one: what is established in people, the key studies, and its status.

From our publisherAMINOSWORK, the research peptide supplier behind Peptide Guardian, posts its third-party lab reports by lot number. Open the lab report library

Kisspeptin

Early human trials

Kisspeptin is a natural human hormone that acts as the master switch for the reproductive hormone system; it has been given to several hundred people in small physiology studies and early trials, mostly in London and Boston, but no kisspeptin medicine is approved anywhere and the version usually sold online, kisspeptin-10, was unanimously rejected by an FDA advisory committee in 2024.

What is established is narrow but solid: kisspeptin is the switch that turns on the reproductive hormone axis, and giving it to people raises LH and FSH within minutes, more strongly in men than in women, and in women only at certain points in the menstrual cycle. What is not established is that it treats anything. The most advanced work is kisspeptin-54 as an egg-maturation trigger in IVF, tested in trials of 53 and 60 women at a single London centre, open-label and without a head-to-head comparison against the standard trigger. The brain-imaging and sexual-desire trials in people with hypoactive sexual desire disorder were small single-exposure crossover studies measuring brain activity, not treatment trials. In the group most often invoked online, men whose reproductive axis has failed, kisspeptin produced no response at all. Repeated or continuous exposure loses its effect within days to weeks. Total human exposure is in the low hundreds of people, almost always for a day or less; the longest published study ran for 12 days. No kisspeptin medicine is approved anywhere.

Key studies

  • Human trial, 2026. The most recent human study of the form usually sold, and the longest. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2025. Kisspeptin-54 given by the non-injected method named in the title raised LH (the pituitary hormone that drives the testes and ovaries) in every group compared with placebo: average extra rise 3.1 units per litre in healthy men (p = 0.002), 1.0 in healthy women (p = 0.004) and 4.3 in women with hypothalamic amenorrhoea (p < 0.001). Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2025. Kisspeptin raised LH strongly (p < 0.001), showing it was active, but compared with placebo it did not change anxiety on a standard questionnaire (p = 0.13), stress hormone cortisol (p = 0.73), blood pressure or heart rate. Source: pubmed.ncbi.nlm.nih.gov
FDA status
Not approved anywhere. FDA lists kisspeptin-10 as a compounding substance that may present significant safety risks.
In sport
Prohibited at all times for male athletes; named in S2.2.1, 2026 and 2027.

All 18 studies on the Kisspeptin page

PT-141 (bremelanotide)

Approved medicine

PT-141 is the code name for bremelanotide, a man-made peptide that switches on melanocortin receptors; it is an FDA-approved prescription medicine (Vyleesi) for low sexual desire in premenopausal women, with a modest effect in two large trials, and the "PT-141" sold online is not that approved medicine.

Two identical 24-week placebo-controlled trials in 1,267 premenopausal women with HSDD found that bremelanotide improved desire and distress scores more than placebo, which led to FDA approval in 2019. The extra benefit over placebo was small (about a third of a point on a 1.2 to 6 desire scale), the number of satisfying sexual events did not improve, and far more women on the drug stopped early, often because of nausea. A one-year extension had no placebo group. There is no approval for men, the published trials in men are small, early or under an expression of concern, and none of the human studies tested the "PT-141" products sold online.

Key studies

  • Human trial, 2022. Compared with placebo, the drug increased reported sexual desire for up to 24 hours. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2020. Pre-treatment with oral ondansetron did not reduce the rate of nausea compared with placebo. Source: dailymed.nlm.nih.gov
  • Human trial, 2019. Desire was measured on the Female Sexual Function Index desire score (range 1.2 to 6) and distress on one question about being bothered by low desire (range 0 to 4). Source: pubmed.ncbi.nlm.nih.gov
FDA status
Approved prescription medicine (Vyleesi) for low desire in premenopausal women only. Online "PT-141" is unapproved.
In sport
Not named on the 2026 or 2027 Prohibited List; no WADA ruling found.

All 13 studies on the PT-141 (bremelanotide) page

Before you trust any seller

A study tells you about the compound. It tells you nothing about what is in a particular vial. How to read a lab report

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sign up and it opens right away.